Article Details

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Retrieved on: 2024-08-19 14:35:35

Tags for this article:

Click the tags to see associated articles and topics

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL. View article details on hiswai:

Excerpt

The trials included 5 groups of interventions: BTKi, PI3K inhibitors (PI3Ki), BCL2 antagonists, anti-CD20 monoclonal antibodies, and other therapies.

Article found on: www.ajmc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up